Lateral internal sphincterotomy (LIS) is a minimally invasive procedure used to treat chronic anal fissures. It involves cutting the internal sphincter muscle, which is located between the rectum and the anus. This procedure is used to reduce spasm and pain, as well as to promote healing of the fissure. While it is an effective treatment option, it is not without risks. This article will explore the benefits and risks of LIS in order to help doctors better understand this procedure and its potential impact on their patients.
Lateral internal sphincterotomy (LIS) is a surgical procedure used to treat chronic anal fissures. It involves cutting the internal sphincter muscle, which is located between the rectum and the anus. This procedure is used to reduce spasm and pain, as well as to promote healing of the fissure. The procedure is typically performed under general anesthesia. During the procedure, the surgeon makes a small incision in the sphincter muscle and then divides it in two. This reduces the tension in the muscle, which helps to reduce spasm and pain, as well as to promote healing of the fissure. The procedure is typically performed as an outpatient procedure and takes about 30 minutes to complete. After the procedure, patients typically experience some pain, bleeding, and swelling for a few days.
Lateral internal sphincterotomy is an effective treatment option for chronic anal fissures. The procedure helps to reduce spasm and pain, as well as to promote healing of the fissure. It is also a minimally invasive procedure, which means that it has a shorter recovery time and fewer risks than more invasive surgical procedures. The procedure is also relatively safe. The risks associated with the procedure are typically minor and include pain, bleeding, infection, and swelling. The procedure is also relatively cost-effective, as it is typically performed as an outpatient procedure.
Although the procedure is relatively safe, there are some risks associated with LIS. These risks include pain, bleeding, infection, and swelling. In rare cases, the procedure can also cause damage to the nerves or muscles in the area, which can lead to incontinence or other complications. Additionally, the procedure can cause scarring, which can lead to narrowing of the anal canal.
Lateral internal sphincterotomy is a minimally invasive procedure used to treat chronic anal fissures. The procedure is effective in reducing spasm and pain, as well as promoting healing of the fissure. It is also relatively safe and cost-effective. However, there are some risks associated with the procedure, including pain, bleeding, infection, swelling, nerve or muscle damage, and scarring. Doctors should weigh the risks and benefits of LIS when considering this procedure for their patients.
1.
Even when they are not paying attention, children are still learning.
2.
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
3.
Kate Middleton Reaches Cancer Treatment Milestone
4.
Pulled Myeloma Drug Improves Survival in Trial
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
Breast Cancer Secrets: AI-Powered Precision Medicine
2.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
3.
Surprising Symptoms of Prostate Cancer: What You Need to Know
4.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation